Objective: To systematically evaluate the clinical efficacy and safety of oral Dushiqingre Decoction combined with topical antipruritic lotion in the treatment of seborrheic dermatitis of the scalp (damp-heat syndrome), providing an economically effective therapeutic option for community healthcare. Methods: A randomized controlled study was conducted, enrolling 112 patients with seborrheic dermatitis of the scalp (damp-heat syndrome) from a community health service center between March 2024 and August 2025. The patients were randomly divided into a treatment group (n=56) and a control group (n=56). The treatment group received oral Dushiqingre Decoction (1 dose daily, divided into two doses) combined with topical antipruritic lotion (3 times weekly, 10 minutes per application), while the control group received topical 2% ketoconazole lotion (3 times weekly, 5 minutes per application). Both groups underwent a 4-week treatment course. Observation indicators included: scores for primary symptoms (scalp oiliness, erythema, scaling, pruritus), Dermatology Life Quality Index (DLQI), and adverse reactions. Results: After treatment, the total effective rate in the treatment group was 91.07%, significantly higher than the 75.00% in the control group (P<0.05). Both groups showed significant improvement in primary symptom scores and DLQI scores compared to baseline (P<0.05), with the treatment group demonstrating greater improvement than the control group (P<0.05). No severe adverse reactions were reported in either group. Conclusion: The combination of oral Dushiqingre Decoction and topical antipruritic lotion is effective in treating seborrheic dermatitis of the scalp (damp-heat syndrome), significantly improving clinical symptoms with good safety profile, making it suitable for widespread application in community healthcare.